Company intelligence
Faron
A CLEVER Approach to Fight Cancer.
About Faron
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.
Verified activity
Signals from Faron
4 published signals
Presence & Recognition
Faron Pharmaceuticals CEO Juho Jalkanen MD, PhD, will speak at the H.C. Wainwright & Co 28th Annual Global Investment Conference in New York on September 14-16.
Reported by Faron
Presence & Recognition
Faron announced that Dr. Heme will answer common questions about blood cancers during Blood Cancer Awareness Month in September.
Reported by Faron
Research & Knowledge
Faron launched The Faron Blog to share context, science, and insights from the team on bexmarilimab and the first half of the year
Reported by Faron
Products & Services
Faron launched a new blog on its website to follow what leaders are thinking and latest developments in the field.
Reported by Ralph Hughes